Home > Compound List > Compound details
1089283-49-7 molecular structure
click picture or here to close

N-(2,6-difluorophenyl)-5-{3-[2-({5-ethyl-4-[4-(4-methanesulfonylpiperazin-1-yl)piperidin-1-yl]-2-methoxyphenyl}amino)pyrimidin-4-yl]imidazo[1,2-a]pyridin-2-yl}-2-methoxybenzamide

ChemBase ID: 72503
Molecular Formular: C44H47F2N9O5S
Molecular Mass: 851.9630864
Monoisotopic Mass: 851.33889309
SMILES and InChIs

SMILES:
c1c(c(c(cc1)F)NC(=O)c1c(ccc(c1)c1c(n2c(n1)cccc2)c1ccnc(n1)Nc1c(cc(c(c1)CC)N1CCC(CC1)N1CCN(CC1)S(=O)(=O)C)OC)OC)F
Canonical SMILES:
COc1cc(N2CCC(CC2)N2CCN(CC2)S(=O)(=O)C)c(cc1Nc1nccc(n1)c1c(nc2n1cccc2)c1ccc(c(c1)C(=O)Nc1c(F)cccc1F)OC)CC
InChI:
InChI=1S/C44H47F2N9O5S/c1-5-28-26-35(38(60-3)27-36(28)53-19-15-30(16-20-53)52-21-23-54(24-22-52)61(4,57)58)49-44-47-17-14-34(48-44)42-40(50-39-11-6-7-18-55(39)42)29-12-13-37(59-2)31(25-29)43(56)51-41-32(45)9-8-10-33(41)46/h6-14,17-18,25-27,30H,5,15-16,19-24H2,1-4H3,(H,51,56)(H,47,48,49)
InChIKey:
MOSKATHMXWSZTQ-UHFFFAOYSA-N

Cite this record

CBID:72503 http://www.chembase.cn/molecule-72503.html

Collapse All Expand All

NAMES AND DATABASE IDS

NAMES AND DATABASE IDS

Names Database IDs
IUPAC name
N-(2,6-difluorophenyl)-5-{3-[2-({5-ethyl-4-[4-(4-methanesulfonylpiperazin-1-yl)piperidin-1-yl]-2-methoxyphenyl}amino)pyrimidin-4-yl]imidazo[1,2-a]pyridin-2-yl}-2-methoxybenzamide
IUPAC Traditional name
N-(2,6-difluorophenyl)-5-{3-[2-({5-ethyl-4-[4-(4-methanesulfonylpiperazin-1-yl)piperidin-1-yl]-2-methoxyphenyl}amino)pyrimidin-4-yl]imidazo[1,2-a]pyridin-2-yl}-2-methoxybenzamide
Synonyms
GSK1904529A
CAS Number
1089283-49-7
PubChem SID
162037428
PubChem CID
25124816

DATA SOURCES

DATA SOURCES

All Sources Commercial Sources Non-commercial Sources
Data Source Data ID Price
Selleck Chemicals
S1093 external link Add to cart Please log in.
Data Source Data ID
PubChem 25124816 external link

CALCULATED PROPERTIES

CALCULATED PROPERTIES

JChem
Acid pKa 7.4687777  H Acceptors 11 
H Donor LogD (pH = 5.5) 4.050573 
LogD (pH = 7.4) 5.163865  Log P 5.1666265 
Molar Refractivity 232.7757 cm3 Polarizability 89.62956 Å3
Polar Surface Area 146.53 Å2 Rotatable Bonds 11 
Lipinski's Rule of Five false 

PROPERTIES

PROPERTIES

Physical Property Safety Information Pharmacology Properties Product Information Bioassay(PubChem)
Solubility
DMSO expand Show data source
Storage Condition
-20°C expand Show data source
Target
IGF-1R expand Show data source
Salt Data
Free Base expand Show data source

DETAILS

DETAILS

Selleck Chemicals Selleck Chemicals
Selleck Chemicals - S1093 external link
Research Area
Description Cancer
Biological Activity
Description GSK1904529A is a selective inhibitor of IGF-IR and IR with IC50 of 27 nM and 25 nM, respectively.
Targets

IGF-IR

IR

IC50

27 nM

25 nM [1]

In Vitro GSK1904529A is a reversible, ATP-competitive inhibitor and has enzyme-inhibitor binding values against IGF-IR and IR with Ki of 1.6 nM and 1.3 nM, respectively. GSK1904529A potently inhibits the ligand-induced phosphorylation of IGF-IR and IR at concentrations above 0.01 μM, followed by blocking downstream signaling (AKT, IRS-1, and ERK). GSK1904529A potently inhibits NIH-3T3/LISN, TC-71, SK-N-MC, SK-ES RD-ES cells with IC50 of 60 nM, 35 nM, 43 nM, 61 nM and 62 nM, respectively. GSK1904529A also inhibits other multiple myeloma and Ewing’s sarcoma cell lines including NCI-H929, MOLP-8, LP-1and KMS-12-BM etc. GSK1904529A induces cell cycle arrest at the G1 phase in cell lines COLO 205, MCF-7, and NCI-H929, which are sensitive to GK1904529A. [1]
In Vivo GSK1904529A indicates 98% tumor growth inhibition in NIH-3T3/LISN tumor-bearing mice at a dose of 30 mg/kg (orally, twice-daily) and 75% in COLO 205 xenografts mice (once daily). Among HT29 and BxPC3 xenografts, GSK1904529A produces moderate tumor growth inhibition with no side effects at a dose of 30 mg/kg. Meanwhile, GSK1904529A shows minimal effects on blood glucose levels. GSK1904529A (~3.5 μM in blood) completely inhibits IGF-IR phosphorylation. GSK1904529A has been implicated in treatment of various IGF-IR-dependent tumors including prostate, colon, breast, pancreatic, ovarian, and sarcomas. [1]
Clinical Trials
Features
Protocol
Kinase Assay [1]
Kinase assays GSK1904529A is dissolved in DMSO as stock solution at 10 mM. Baculovirus-expressed glutathione S-transferase-tagged proteins encoding the intracellular domain of IGF-IR (amino acids 957-1367) and IR (amino acids 979-1382) are used for determination of IC50. Kinases are activated by preincubating the enzyme (2.7 μM final concentration) in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1mg/mL bovine serum albumin, and 2 mM ATP. GSK1904529A is diluted in DMSO and dispensed into the assay plates (100 nL/well). Kinase reactions contained (in 10 μL) 50 mM HEPES (pH 7.5), 3 mM DTT, 0.1mg/mL bovine serum albumin, 1mM CHAPS, 10 mM MgCl2, 10 μM ATP, 500 nM substrate peptide (biotin-aminohexylAEEEEYMMMMAKKKK-NH2; QPC), and 0.5 nM activated enzyme. Reactions are stopped after 1 hour at room temperature with 33 μM EDTA. Peptide phosphorylation is measured by time-resolved fluorescence resonance energy transfer with 7 nM streptavidin Surelight allophycocyanin and 1nM europium-conjugated phosphotyrosine antibodies. Plates are read in a multilabel reader.
Cell Assay [1]
Cell Lines Tumor cell lines including multiple myeloma, ewing's sarcoma, askin's tumor, colon, breast, anaplastic large cell lymphoma, lung, cervix, head and neck, prostate and ovary.
Concentrations ~ 100 μM, stocked in DMSO at 10 mM.
Incubation Time 72 hours
Methods Cells are seeded in 96-well plates and incubated overnight at 37 °C, and treated with various concentrations of GSK1904529A for 72 hours. For the NIH-3T3/LISN, cells are seeded on collagen-coated 96-well tissue culture plates and allowed to adhere for 24 hours. The tissue culture medium is replaced with serum-free medium and the cells are treated with DMSO or GSK1904529A for 2 hours. IGF-I (30 ng/mL) is added and the cells are incubated at 37 °C for 72 hours. Cell proliferation is quantified using the CellTiter-Glo Luminescent Cell Viability Assay. IC50 values are determined.
Animal Study [1]
Animal Models NIH-3T3/LISN, COLO 205, HT29, and BxPC3 cells are implanted s.c. into the right flank of 8- to 10-wk-old female nu/nu CD-1athymic mice.
Formulation Formulated in 20% sulfobutylether-h-cyclodextrin (pH 3.5; ISP)
Doses ~30 mg/kg
Administration Orally administered
References
[1] Sabbatini P, et al. Clin Cancer Res, 2009, 15(9), 3058-3067.

REFERENCES

REFERENCES

From Suppliers Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • Searching...Please wait...

PATENTS

PATENTS

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

INTERNET

INTERNET

Baidu iconBaidu google iconGoogle